The Vascular effects of Infection in Pediatric Stroke (VIPS II) Study

-
Investigator: Heather J. Fullerton, MD
Sponsor: NIH National Institute of Neurological Disorders and Stroke

Location(s): United States

Description

The VIPS study found that minor infections like the common cold act as a trigger for ischemic stroke in children, while routine childhood vaccinations are protective. The VIPS renewal will identify the specific organisms and inflammatory mediators involved in childhood stroke and guide the development of targeted stroke prevention strategies, such as treatment with antivirals, antibiotics, and anti-inflammatory medications. Mounting data show that infection plays a role in a broad range of vascular diseases; hence, the results of this study will not only help the ≈2,000 U.S. children afflicted by stroke every year, but also shed light on the mechanisms underlying many other vascular diseases in children and adults.

Pediatric arterial ischemic stroke afflicts ≈2,000 U.S. children every year, permanently disabling most, yet is poorly understood. The Vascular effects of Infection in Pediatric Stroke (VIPS I) study established an international network of 37 sites and enrolled 355 children with stroke and 354 controls. We discovered: (a) minor clinical infections act as a stroke trigger, while routine childhood vaccinations are protective; (b) almost half of children with stroke have an acute herpesvirus infection (the cause of chicken pox, cold sores, and other common illnesses); and (c) children with stroke have a high risk of recurrent stroke, particularly if they have an arteriopathy. A VIPS pilot study suggests that other common childhood pathogens may also play a role, possibly in combination with herpesviruses. The full spectrum of pathogens that contribute to childhood stroke risk remains unknown. Infection is compelling as a treatable stroke risk factor, with available therapies for both pathogens and downstream inflammatory effects. However, VIPS findings present a paradox: infection is common, while childhood stroke is uncommon. Possible explanations are (1) the “infection hypothesis”: unusual pathogen strains, or combinations of pathogens, lead to stroke; and (2) the “host response hypothesis”: an unusual inflammatory response to infection leads to stroke. A thorough understanding of both the specific pathogens and inflammatory mediators underlying childhood stroke pathogenesis, particularly arteriopathic stroke, is needed to develop strategies to reduce recurrent stroke in children. Broad testing for infections through traditional methods is prohibitively costly, and requires preconceived assumptions about the pathogens involved. Next generation sequencing (NGS) allows for the efficient, highly sensitive and unbiased detection of any pathogen, known or novel, by sequencing all nucleic acids in a biological sample and matching them with genomes in a reference database. Multiplex bead arrays can efficiently test for a large number of immune mediators on small blood samples. VIPS II, the continuation of VIPS, will use these techniques to address the paradox of infection as a risk factor for childhood stroke, and to better understand the causes of arteriopathies in children. Our overall hypothesis is that differences in pathogens and host inflammatory responses underlie different stroke subtypes, and hence recurrence risk. The specific aims are to (1) identify known and novel pathogens in children with stroke, and determine whether different pathogens are associated with arteriopathic versus other stroke types; and (2) to determine whether children with arteriopathic stroke have a distinct analyte signature suggesting an alternative pathway of inflammation compared to children with other stroke types. The goal of VIPS II is to gain the knowledge needed to protect children with stroke from additional brain injury. Its results will guide the selection of currently available therapies—such as antimicrobials and anti-inflammatory medications—for a secondary stroke prevention trial.